TransCode opens Phase 1 Cohort 3; PK/PD from Cohort 1 show 66% miR-10b inhibition at 24h

Transcode Therapeutics, Inc.

Safety Review Committee approved third cohort after no significant safety/DLTs in Cohort 2.
Cohort 3 dose will be approximately double the Cohort 2 dose; enrollment ongoing.
Cohort 1 PK/PD data consistent with preclinical and Phase 0; 66% miR-10b inhibition at 24h post-infusion.
Plasma concentration of TTX-MC138 in humans exceeded nonclinical levels, suggesting favorable PK.
Several patients from Cohorts 1 and 2 remain on study for continued treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.